歡迎光臨源葉生物,登錄 | 注冊(cè) |
當(dāng)前位置: 首頁(yè) > 小分子抑制劑 > DNADamage/DNARepair > Karenitecin

瀏覽歷史

S89555

Karenitecin

源葉(MedMol) 98%
  • 英文名:
  • Karenitecin
  • 別名:
  • (4S)-4-乙基-4-羥基-11-(2-三甲基硅基)乙基)-1H-吡喃并[3',4':6,7]氮茚并[1,2-B]喹啉-3,14(4H,12H)-二酮;BNP 1350; Cositecan; UNII-24R60NVC41;
  • CAS號(hào):
  • 203923-89-1
  • 分子式:
  • C25H28N2O4Si
  • 分子量:
  • 448.58632
  • MDL:
  • MFCD09833216
品牌貨號(hào)產(chǎn)品規(guī)格價(jià)格(RMB) 庫(kù)存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購(gòu)物車...
源葉(MedMol) S89555-5mg 98% ¥5500.00元 預(yù)計(jì)交期:3-5天 - - - EA 加入購(gòu)物車
源葉(MedMol) S89555-10mg 98% ¥8500.00元 預(yù)計(jì)交期:3-5天 - - - EA 加入購(gòu)物車
大包裝詢價(jià)

提交您的電話號(hào)碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 產(chǎn)品描述: Karenitecin (Cositecan) is a topoisomerase I inhibitor, with potent anti-cancer activity.
  • 靶點(diǎn): Topoisomerase I;Topoisomerase
  • 體外研究:
    Karenitecin is a topoisomerase I inhibitor, with potent anti-cancer activity. Karenitecin inhibits cell growth of A253 cells with IC10, IC50, and IC90 values of 0.01, 0.07, and 0.7 μM after 2 h treatment. Karenitecin induces DNA damage (0.01, 0.07, and 0.7 μM), and increases cyclin E and cdk2 protein expression in A253 cells (0.07, and 0.7 μM). Karenitecin markedly enhances the cyclin B/cdc2-associated kinase activity at low concentration, but slightly suppresses this kinase activity at higher concentration. Karenitecin inhibits several human colon cancer cell lines such as COLO205, COLO320, LS174T, SW1398 and WiDr cells, with IC50s of 2.4 nM, 1.5 nM, 1.6 nM, 2.9 nM, and 3.2 nM, respectively
  • 體內(nèi)研究:
    Karenitecin shows maximum growth inhibition of 61% on COLO320 cells and 54% on COLO205 colon cancer cells via i.p. administration of 1 mg/kg in mice. Karenitecin (1.0 mg/kg daily × 5 i.p.) significantly suppresses growth inhibition both in the parental Pgp-negative xenografts and in the Pgp-positive xenografts
  • 參考文獻(xiàn):
    1. Yin MB, et al. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol. 2000 Mar;57(3):453-9. 2. Van Hattum AH, et al. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer. 2000 Oct 15;88(2):260-6.
  • 溶解性: Soluble  in  DMSO
  • 保存條件: 2-8℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.229 ml 11.146 ml 22.292 ml
    5 mM 0.446 ml 2.229 ml 4.458 ml
    10 mM 0.223 ml 1.115 ml 2.229 ml
    50 mM 0.045 ml 0.223 ml 0.446 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
  • 產(chǎn)品描述: Karenitecin (Cositecan) is a topoisomerase I inhibitor, with potent anti-cancer activity.
  • 靶點(diǎn): Topoisomerase I;Topoisomerase
  • 體外研究:
    Karenitecin is a topoisomerase I inhibitor, with potent anti-cancer activity. Karenitecin inhibits cell growth of A253 cells with IC10, IC50, and IC90 values of 0.01, 0.07, and 0.7 μM after 2 h treatment. Karenitecin induces DNA damage (0.01, 0.07, and 0.7 μM), and increases cyclin E and cdk2 protein expression in A253 cells (0.07, and 0.7 μM). Karenitecin markedly enhances the cyclin B/cdc2-associated kinase activity at low concentration, but slightly suppresses this kinase activity at higher concentration. Karenitecin inhibits several human colon cancer cell lines such as COLO205, COLO320, LS174T, SW1398 and WiDr cells, with IC50s of 2.4 nM, 1.5 nM, 1.6 nM, 2.9 nM, and 3.2 nM, respectively
  • 體內(nèi)研究:
    Karenitecin shows maximum growth inhibition of 61% on COLO320 cells and 54% on COLO205 colon cancer cells via i.p. administration of 1 mg/kg in mice. Karenitecin (1.0 mg/kg daily × 5 i.p.) significantly suppresses growth inhibition both in the parental Pgp-negative xenografts and in the Pgp-positive xenografts
  • 參考文獻(xiàn):
    1. Yin MB, et al. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol. 2000 Mar;57(3):453-9. 2. Van Hattum AH, et al. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer. 2000 Oct 15;88(2):260-6.
  • 溶解性: Soluble  in  DMSO
  • 保存條件: 2-8℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.229 ml 11.146 ml 22.292 ml
    5 mM 0.446 ml 2.229 ml 4.458 ml
    10 mM 0.223 ml 1.115 ml 2.229 ml
    50 mM 0.045 ml 0.223 ml 0.446 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。
点击收缩